5 Best Healthcare AI Stocks to Buy According to Analysts

1. Intuitive Surgical, Inc. (NASDAQ:ISRG)

On April 23, 2026, Barclays lowered its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $651 from $712 while maintaining an Overweight rating following the company’s Q1 results. The firm said the quarter delivered a “strong fundamental beat,” driven by procedure growth and system placements.

A day earlier, Baird raised its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $610 from $575 and kept an Outperform rating. The firm updated its model after the company’s beat-and-raise quarter, though it cautioned that broader MedTech sentiment could weigh on the stock.

On April 21, 2026, Intuitive Surgical reported Q1 adjusted EPS of $2.50, well above consensus estimates of $2.11, while revenue rose to $2.77 billion from expectations of $2.62 billion. Worldwide procedures across the da Vinci Surgical System and Ion System platforms grew about 17% year over year. Da Vinci procedures increased approximately 16%, while Ion procedures rose around 39%. The company placed 431 da Vinci systems during the quarter, up from 367 a year earlier, including 232 da Vinci 5 systems compared to 147 in the prior-year period. It also placed 52 Ion systems, up from 49 last year.

For full-year 2026, Intuitive Surgical expects da Vinci procedure growth of about 13.5% to 15.5%, a non-GAAP gross margin of 67.5% to 68.5% of revenue, and operating expense growth of 11% to 14%. The margin outlook includes an estimated 1% revenue impact from tariffs.

Intuitive Surgical, Inc. (NASDAQ:ISRG) develops robotic-assisted surgical systems and related technologies aimed at expanding access to minimally invasive care globally.

READ NEXT: 8 Best Beginner Stocks to Buy Right Now and 10 Fastest-Growing Financial Stocks to Invest In

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.